Olive Leaf Extract May Supercharge Immune Cells Against Colorectal Cancer

Researchers in Türkiye have found that olive leaf extract, long studied for its direct anticancer properties, may work best as an immune amplifier rather than a standalone treatment. In a new laboratory study published in the Iranian Journal of Immunology, Sisman, Sendul, and Kocyigit report that low, non-toxic concentrations of olive leaf extract significantly enhanced the ability of natural killer cells to destroy human colorectal cancer cells, a finding that reframes how scientists might use this botanical compound therapeutically.

Olive Leaf Extract Boosts NK-92 Cell Killing of HT-29 Tumor Cells

The core result is specific: olive leaf extract at 100 and 200 micrograms per milliliter, concentrations that did not harm the immune cells themselves, significantly increased the cytotoxic activity of NK-92 cells against HT-29 human colorectal adenocarcinoma cells. To confirm the mechanism, the team measured granzyme B and perforin, the molecular weapons that natural killer cells deploy to punch holes in tumor cells and trigger programmed death. Both proteins rose significantly after OLE treatment, suggesting the extract actively primed the NK cells rather than simply standing aside.

Olive leaf extract is rich in two polyphenols, oleuropein and hydroxytyrosol. Prior work has shown these compounds can induce apoptosis and block the cell cycle in several cancer types, including colon adenocarcinoma. The problem has always been dose: direct killing of tumor cells requires concentrations that are difficult to achieve safely in a living organism. What this study adds is a lower-dose pathway, one that works through the immune system rather than against the tumor directly.

Colorectal Cancer Urgency Makes Every New Lead Count

Colorectal cancer is the third most commonly diagnosed cancer in the United States. In 2023 alone, 155,662 new cases were reported, with more than 54,000 deaths recorded in 2024. Five-year survival climbs sharply when the disease is caught early, but many patients are diagnosed at later stages when treatment options narrow. That clinical pressure gives any credible immunological angle added urgency.

NK cells are a front-line defense. Unlike T cells, they do not need prior exposure to a specific tumor antigen to act; they can recognize and kill abnormal cells almost immediately. Enhancing their potency with a well-tolerated botanical compound, if the effect translates out of the lab, could complement existing immunotherapy approaches without the toxicity profile of conventional chemotherapy.

How the Team Isolated the Immune-Boosting Signal

The study used the NK-92 cell line, an established model in NK cell therapy research that is amenable to genetic engineering and well-characterized as an effector cell platform. Olive leaves were sourced from Balıkesir, Türkiye, dried, and extracted with 70% methanol. Cell viability was measured using both MTT and ATP assays, giving two independent readouts of toxicity and proliferation. Cytotoxic activity was then assessed in a direct co-culture system where NK-92 cells and HT-29 cancer cells were placed together, and killing efficiency was recorded.

The IC50 value for OLE against HT-29 cells, the concentration that kills half the tumor cells outright, was 548 micrograms per milliliter. Crucially, concentrations below that threshold (100 to 200 micrograms per milliliter) actually promoted NK-92 proliferation rather than harming the immune cells. That bifurcation is the mechanistic pivot of the paper: a dose window exists where OLE spares and stimulates the immune effectors while still making them more lethal to the tumor.

The in vitro anticancer properties of olive leaf polyphenols have been documented across multiple cell lines, including colorectal adenocarcinoma, lending biological plausibility to the granzyme B and perforin results seen here.

Significant Caveats Remain Before Any Clinical Claim

This is early-stage, cell-culture research. In vitro models do not fully replicate the three-dimensional tumor microenvironment, the vascular supply, or the immunosuppressive signals that tumors generate inside a living body. The NK-92 line is a useful proxy for NK cell biology, but it is an immortalized cancer-derived line, not primary NK cells drawn from patient blood. Granzyme B and perforin levels in a dish may not predict what happens when those same cells encounter the physical and chemical barriers of a real tumor.

Bioavailability remains the central unresolved challenge. Getting oleuropein and hydroxytyrosol to target tissues at therapeutic concentrations after oral ingestion or intravenous delivery is an active area of research, not a solved problem. The authors frame their findings as a step toward demonstrating that physiologically achievable doses, rather than supraphysiological ones, might be sufficient if the immune-enhancement route is pursued instead of direct cytotoxicity.

The Path From Polyphenol to Potential Therapy

The natural next steps include testing OLE-primed NK cells in three-dimensional tumor spheroid models and, eventually, in animal models of colorectal cancer. Formulation work to improve bioavailability, through nanoencapsulation or other delivery strategies, would be needed before any human application is meaningful. Translating natural product findings into clinical trials carries well-documented challenges, including the need to standardize extract composition, define dosing regimens, and demonstrate safety over time.

Still, the conceptual contribution is real. By showing that a non-toxic polyphenol concentration can amplify granzyme B and perforin output in NK cells, the study shifts the conversation about olive leaf extract from "how do we deliver enough to kill cancer cells directly" to "can we use it to make immune cells better at doing what they already do." That is a more tractable therapeutic question, and in the search for adjuncts to colorectal cancer treatment, tractable questions matter.

Evidence rating

INVESTIGATIONAL — 67/100

Caveats:

• Funding was not disclosed by the authors.

In vitro cell-line study using NK-92 and HT-29 co-cultures. All findings are limited to controlled laboratory conditions; no animal or human data are presented, so results cannot be extrapolated to clinical outcomes. The study has not been independently replicated, and funding was not disclosed.

References

1. Sisman G, Sendul A, Kocyigit A (2026). Olive Leaf Extract Enhances Natural Killer Cell-Mediated Cytotoxicity against Colorectal Cancer Cells. Iranian journal of immunology : IJI. https://doi.org/10.22034/iji.2026.109489.3151
2. Weixiong Zhu, Chuanlei Fan, Yongqing Zhao, et al. (2025). The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies. Cancer Cell International. https://doi.org/10.1186/s12935-025-03980-y
3. U.S. Cancer Statistics Colorectal Cancer Stat Bite – CDC. cdc.gov. https://www.cdc.gov/cancer/colorectal/statistics/index.htm
4. Heloisa Rodrigues Pessoa, Lilia Zago, Graziana Difonzo, Antonella Pasqualone, Francesco Caponio, Danielly C. Ferraz da Costa (2024). Olive Leaves as a Source of Anticancer Compounds: In Vitro Evidence and Mechanisms. Molecules. https://doi.org/10.3390/molecules29174249
5. Nina Antunes, Banani Kundu, Subhas C. Kundu, Rui L. Reis, Vítor Correlo (2022). In Vitro Cancer Models: A Closer Look at Limitations on Translation. Bioengineering. https://doi.org/10.3390/bioengineering9040166
6. Challenges of Conducting Clinical Trials of Natural Products to Combat Cancer – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073166/